Company Encyclopedia
View More
name
Alaunos Therapeutics
TCRT.US
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations.
1.944 T
TCRT.USMarket value -Rank by Market Cap -/-

Financial Score

24/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking325/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-145.65%E
    • Profit Margin-67083.33%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-14.29%E
    • Net Profit YoY65.83%A
    • Total Assets YoY4.90%C
    • Net Assets YoY2.90%C
  • Cash ScoreD
    • Cash Flow Margin-0.15%D
    • OCF YoY-14.29%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio24.73%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Alaunos Therapeutics Settles Outstanding Invoices with MD Anderson for $285,055

    Alaunos Therapeutics Inc. has settled disputes with The University of Texas M.D. Anderson Cancer Center over unpaid invoices from a 2019 agreement. The settlement involves Alaunos paying $285,055 in installments from December 2025 to May 2026, with mutual releases of claims. This information was published by Alaunos via the SEC's EDGAR system.

    Reuters·
    US
    TCRT
    +3.53%
    Reuters·
    US
    TCRT
    +3.53%

    U.S. stock market quick update: Alaunos Therapeutics up 8.92%

    Alaunos Therapeutics rose 8.92%; Akero Therapeutics rose 16.43%, with a transaction volume of USD 1.792 billion; AbbVie fell 0.02%, with a transaction volume of USD 531 million; Global Health Solutions rose 24.86%, with a transaction volume of 376,371,013; Biodexa Pharmaceuticals rose 44.10%, with a market value of USD 68.83 billion

    Tracking Unusual Activity·
    US
    TCRT
    +3.53%
    Tracking Unusual Activity·
    US
    TCRT
    +3.53%

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    In Thursday's pre-market session, several health care stocks saw significant movements. Bluejay Diagnostics (BJDX) surged 113.4% to $3.99, while Alaunos Therapeutics (TCRT) rose 27.83% to $4.73. Telomir Pharmaceuticals (TELO) increased by 26.63% to $2.09, and Biodexa Pharmaceuticals (BDRX) gained 21.53% to $9.37. Akero Therapeutics (AKRO) saw a rise of 17.68% to $54.71, and Adaptimmune Therapeutics (ADAP) climbed 16.1% to $0.24. The article also notes the market values of these companies' outstanding shares.

    Benzinga·
    US
    BDRX
    -12.38%
    US
    AKRO
    0.00%
    US
    TELO
    +1.43%
    Benzinga·
    US
    BDRX
    -12.38%
    US
    AKRO
    0.00%
    US
    TELO
    +1.43%

    4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week

    Several biotech stocks have experienced a decline in their Momentum scores over the past week, indicating weakening strength. Notable stocks include Capricor Therapeutics, which dropped significantly after the FDA rejected its therapy application, and Lava Therapeutics, which faced a rating downgrade following a larger-than-expected loss. Alaunos Therapeutics saw a decline without major news, while Champions Oncology reported disappointing earnings, leading to a drop in its Momentum score. Overall, these stocks show unfavorable trends in Momentum and Value according to Benzinga's Edge Stock Rankings.

    benzinga_article·
    US
    TCRT
    +3.53%
    US
    CSBR
    -0.28%
    benzinga_article·
    US
    TCRT
    +3.53%
    US
    CSBR
    -0.28%

    Alaunos Therapeutics Inc Files For Mixed Shelf Of Up To $50 Million - SEC Filing

    Aug 21 (Reuters) - Alaunos Therapeutics Inc:* ALAUNOS THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $50 MILLION - SEC FILING Source text: Further company coverage:

    Reuters·
    US
    TCRT
    +3.53%
    Reuters·
    US
    TCRT
    +3.53%
    © 2025 Longbridge｜Disclaimer